FHD-609
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Synovial Sarcoma
Conditions
Advanced Synovial Sarcoma
Trial Timeline
Aug 17, 2021 → Dec 4, 2023
NCT ID
NCT04965753About FHD-609
FHD-609 is a phase 1 stage product being developed by Foghorn Therapeutics for Advanced Synovial Sarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04965753. Target conditions include Advanced Synovial Sarcoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04965753 | Phase 1 | Terminated |
Competing Products
20 competing products in Advanced Synovial Sarcoma